Form 4: RxSight Executive Ilya Goldshleger Sells Shares Under 10b5-1 Trading Plan

Ilya Goldshleger, Co-President and COO of RxSight, Inc., executed multiple sales of common stock on August 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 5, 2024, Ilya Goldshleger, Co-President and COO of RxSight, Inc., sold multiple blocks of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2023.
• The transactions involved the sale of 1,145 shares at a weighted average price of $38.8011, 1,855 shares at $39.4258, 1,087 shares at $38.8289, 1,913 shares at $39.5128, 1,827 shares at $39.0429, and 1,173 shares at $39.7293.
• Following these transactions, Goldshleger directly owns 42,246 shares of RxSight common stock.
• Goldshleger's spouse indirectly owns 1,372 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. The use of a 10b5-1 plan suggests a neutral sentiment, as it indicates pre-planned transactions.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests a planned and orderly approach to selling shares, rather than a reaction to immediate market conditions.

Comparison to Industry Standards

• Comparing the trading activity to similar executives at comparable medical device companies would provide context on whether these sales are typical.
• Analyzing the percentage of shares sold relative to Goldshleger's total holdings can indicate the significance of these transactions.
• Reviewing similar Form 4 filings from competitors like Alcon, Johnson & Johnson (Vision Care), or Bausch + Lomb can provide benchmarks for executive stock transactions in the ophthalmology sector.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan may mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates